Sign In
Buy ETNB
$14.84
+0 (+0%)
At Close: Jan 29, 2026
89bio, Inc.: A Big Bet On NASH
01:48pm, Thursday, 10'th Aug 2023
89bio, Inc. is a clinical-stage biotech company focused on developing therapies for liver and cardio-metabolic diseases. The stock surged after top-line data from a Phase 2 study for its primary drug
Are Medical Stocks Lagging 89BIO (ETNB) This Year?
10:53am, Friday, 07'th Jul 2023
Here is how 89BIO (ETNB) and Alimera Sciences (ALIM) have performed compared to their sector so far this year.
Weight-loss drugs in development aim to replace injections with pills
03:21pm, Monday, 26'th Jun 2023
Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills i
89bio shares rise as analysts see improved outlook for NASH treatments
08:29am, Tuesday, 13'th Jun 2023
Shares of clinical-stage biopharma company 89bio Inc. ETNB, +4.38% gained 4.8% premarket on Tuesday as Evercore ISI analysts initiated coverage of the stock with an outperform rating. The company is f
89BIO (ETNB) Just Overtook the 20-Day Moving Average
10:50am, Monday, 29'th May 2023
89BIO (ETNB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ETNB crossed above the 20-day moving average, suggesting a short
89bio: Great Prospects After Excellent Phase 2 Data
04:18am, Sunday, 28'th May 2023
ETNB posted excellent phase 2 data in March. They plan to start a phase 3 trial now.
Wall Street Analysts Predict a 57.05% Upside in 89BIO (ETNB): Here's What You Should Know
11:23am, Friday, 05'th May 2023
The mean of analysts' price targets for 89BIO (ETNB) points to a 57.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i
3 Biotech Buyout Targets to Watch
08:25am, Saturday, 29'th Apr 2023
89bio's stock is up more than 21% this year. Karuna Therapeutics says it plans to file an NDA for its lead therapy this year.
Is 89BIO (ETNB) Outperforming Other Medical Stocks This Year?
11:25am, Thursday, 13'th Apr 2023
Here is how 89BIO (ETNB) and Henry Schein (HSIC) have performed compared to their sector so far this year.
Ra Capital Management Now Owns 18% of 89bio
10:31pm, Friday, 31'st Mar 2023
Fintel reports that Ra Capital Management has filed a 13D/A form with the SEC disclosing ownership of 12.88MM shares of 89bio Inc (ETNB).
A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
11:40pm, Wednesday, 29'th Mar 2023
NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient po
89bio Announces Upsized Pricing Of $275 Million Common Stock Public Offering
10:11am, Saturday, 25'th Mar 2023
89bio announced the pricing of its previously announced underwritten public offering of 16,923,077 shares of its common stock at a public offering price per share of $16.25 The post 89bio Announces Up
Why Shares of 89bio Soared This Week
10:57am, Friday, 24'th Mar 2023
89bio's lead therapy pegozafermin is seen as a treatment for NASH and hypertriglyceridemia. No NASH drug has been approved yet by the FDA.
89bio's public stock offering upsized by 38%, priced at a 4% discount
07:21am, Friday, 24'th Mar 2023
89bio Inc. ETNB, +23.83% said Friday that its public offering of stock, which the biopharmaceutical company launched after a 55% surge in its stock in the past two days, was upsized by about 38%. The
